Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia

Ching Liang Ho, Brijesh Arora, James D. Hoyer, Linda E. Wellik, Ruben Mesa, Ayalew Tefferi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The biologic relevance and prognostic impact of angiogenesis is being increasingly recognized in many solid tumors and hematologic malignancies including myelofibrosis with myeloid metaplasia (MMM). Many cytokines including vascular endothelial growth factor (VEGF) have been implicated for neoangiogenesis in MMM. However, the exact humoral basis remains to be elucidated. We examined the expression of VEGF by immunohistochemistry in a prospective cohort of 66 MMM patients, including six with cellular phase disease, and five normal controls. Contrary to most other hematologic malignancies, the distribution and intensity of staining for VEGF in bone marrow was similar between the MMM patients and controls. Interestingly, all six cellular phase patients displayed significantly increased VEGF expression. Thus, upregulation of angiogenic cytokines other than VEGF such as TGF-β or loss of activity of an anti-angiogenic cytokine might be the dominant pathway of endothelial activation in MMM. However, VEGF might contribute to the process in the early stages of the disease.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalEuropean Journal of Haematology
Volume74
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Vascular Endothelial Growth Factor A
Bone Marrow
Hematologic Neoplasms
Cytokines
Up-Regulation
Immunohistochemistry
Staining and Labeling
Neoplasms

Keywords

  • Angiogenesis
  • Myelofibrosis with myeloid metaplasia
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology

Cite this

Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. / Ho, Ching Liang; Arora, Brijesh; Hoyer, James D.; Wellik, Linda E.; Mesa, Ruben; Tefferi, Ayalew.

In: European Journal of Haematology, Vol. 74, No. 1, 01.01.2005, p. 35-39.

Research output: Contribution to journalArticle

Ho, Ching Liang ; Arora, Brijesh ; Hoyer, James D. ; Wellik, Linda E. ; Mesa, Ruben ; Tefferi, Ayalew. / Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. In: European Journal of Haematology. 2005 ; Vol. 74, No. 1. pp. 35-39.
@article{599df42803e541b9ac07a826ce497f67,
title = "Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia",
abstract = "The biologic relevance and prognostic impact of angiogenesis is being increasingly recognized in many solid tumors and hematologic malignancies including myelofibrosis with myeloid metaplasia (MMM). Many cytokines including vascular endothelial growth factor (VEGF) have been implicated for neoangiogenesis in MMM. However, the exact humoral basis remains to be elucidated. We examined the expression of VEGF by immunohistochemistry in a prospective cohort of 66 MMM patients, including six with cellular phase disease, and five normal controls. Contrary to most other hematologic malignancies, the distribution and intensity of staining for VEGF in bone marrow was similar between the MMM patients and controls. Interestingly, all six cellular phase patients displayed significantly increased VEGF expression. Thus, upregulation of angiogenic cytokines other than VEGF such as TGF-β or loss of activity of an anti-angiogenic cytokine might be the dominant pathway of endothelial activation in MMM. However, VEGF might contribute to the process in the early stages of the disease.",
keywords = "Angiogenesis, Myelofibrosis with myeloid metaplasia, Vascular endothelial growth factor",
author = "Ho, {Ching Liang} and Brijesh Arora and Hoyer, {James D.} and Wellik, {Linda E.} and Ruben Mesa and Ayalew Tefferi",
year = "2005",
month = "1",
day = "1",
doi = "10.1111/j.1600-0609.2004.00355.x",
language = "English (US)",
volume = "74",
pages = "35--39",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia

AU - Ho, Ching Liang

AU - Arora, Brijesh

AU - Hoyer, James D.

AU - Wellik, Linda E.

AU - Mesa, Ruben

AU - Tefferi, Ayalew

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The biologic relevance and prognostic impact of angiogenesis is being increasingly recognized in many solid tumors and hematologic malignancies including myelofibrosis with myeloid metaplasia (MMM). Many cytokines including vascular endothelial growth factor (VEGF) have been implicated for neoangiogenesis in MMM. However, the exact humoral basis remains to be elucidated. We examined the expression of VEGF by immunohistochemistry in a prospective cohort of 66 MMM patients, including six with cellular phase disease, and five normal controls. Contrary to most other hematologic malignancies, the distribution and intensity of staining for VEGF in bone marrow was similar between the MMM patients and controls. Interestingly, all six cellular phase patients displayed significantly increased VEGF expression. Thus, upregulation of angiogenic cytokines other than VEGF such as TGF-β or loss of activity of an anti-angiogenic cytokine might be the dominant pathway of endothelial activation in MMM. However, VEGF might contribute to the process in the early stages of the disease.

AB - The biologic relevance and prognostic impact of angiogenesis is being increasingly recognized in many solid tumors and hematologic malignancies including myelofibrosis with myeloid metaplasia (MMM). Many cytokines including vascular endothelial growth factor (VEGF) have been implicated for neoangiogenesis in MMM. However, the exact humoral basis remains to be elucidated. We examined the expression of VEGF by immunohistochemistry in a prospective cohort of 66 MMM patients, including six with cellular phase disease, and five normal controls. Contrary to most other hematologic malignancies, the distribution and intensity of staining for VEGF in bone marrow was similar between the MMM patients and controls. Interestingly, all six cellular phase patients displayed significantly increased VEGF expression. Thus, upregulation of angiogenic cytokines other than VEGF such as TGF-β or loss of activity of an anti-angiogenic cytokine might be the dominant pathway of endothelial activation in MMM. However, VEGF might contribute to the process in the early stages of the disease.

KW - Angiogenesis

KW - Myelofibrosis with myeloid metaplasia

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=12444281837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444281837&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2004.00355.x

DO - 10.1111/j.1600-0609.2004.00355.x

M3 - Article

C2 - 15613104

AN - SCOPUS:12444281837

VL - 74

SP - 35

EP - 39

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -